Company news
Adhera Therapeutics Inc. (OTC:ATRX) news
Adhera Therapeutics Inc. news releases on 6ix. Latest, Jan 25, 2023: Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta…
Press releases & updates
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
January 25, 2023
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
September 19, 2022
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin
July 19, 2022
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
May 19, 2022
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board
March 21, 2022
OTC Markets Group Welcomes New OTCQB Companies – January 24
January 24, 2022
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
January 20, 2022
Adhera Therapeutics Announces Third Quarter 2019 Financial Results and Operational Highlights
November 18, 2019
Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock
September 26, 2019
Adhera Therapeutics and Indegene Announce Next Gen Commercialization Partnership
September 9, 2019
Adhera and Allegis Pharma Announce Co-Promotion Agreement
September 5, 2019
Adhera Therapeutics Announces Termination of Tender Offer for Warrants
July 2, 2019
Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer
April 4, 2019
Adhera Therapeutics and Alyvant Enter into Digital Co-Promotion Agreement for Prestalia
March 3, 2019
Adhera Therapeutics' DyrctAxessTM Platform Helps 78% of Patients Adhere to PRESTALIA(R); Achieves Exceptionally High Level of Drug Adherence to an Antihypertensive Medication
February 5, 2019
Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update
November 20, 2018
Adhera Therapeutics Selects IQVIA’s OCE Technology Platform to Support Commercial Excellence
November 20, 2018
Marina Biotech Appoints Nancy R. Phelan to the Board of Directors
October 3, 2018
Marina Biotech Appoints Eric Teague as Chief Financial Officer
September 24, 2018
Marina Biotech Appoints Jay D. Schwartz to serve as Senior Vice President, Commercial Operations
August 6, 2018
Marina Biotech Appoints Uli Hacksell, Ph.D. and Robert C. Moscato to Board of Directors
June 29, 2018
Marina Biotech Appoints Robert Moscato to Chief Executive Officer
June 20, 2018
CohBar Announces the Appointment of Dr. Philippe Calais to its Board
June 7, 2018
Marina Biotech Announces a New Publication on Prestalia®
February 27, 2018
Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio
January 16, 2018
Marina Biotech Appoints Isaac Blech to its Board of Directors
November 27, 2017
Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives
October 19, 2017
Marina Biotech Appoints Amit Shah as Chief Financial Officer
October 5, 2017
Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives
August 21, 2017
Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market
August 2, 2017
Marina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform
July 25, 2017
Marina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia®
July 24, 2017
Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics
July 19, 2017
Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman
July 5, 2017
Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)
June 26, 2017
Marina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy
June 6, 2017
Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases
May 30, 2017
Marina Biotech to Participate in Joseph Gunnar's Pioneers 2017 Conference on May 2
April 27, 2017
Marina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer Tablet
April 6, 2017
Marina Biotech Provides Business Update
April 6, 2017
Marina Biotech to Present Data on IT-102 and IT-103 at 2017 American Association for Cancer Research Annual Meeting
March 29, 2017
Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1
March 24, 2017
Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16
March 13, 2017
Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France
March 2, 2017
Marina Biotech to Participate in the 29th Annual ROTH Conference
March 1, 2017
Marina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel
February 28, 2017
Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer
February 21, 2017
Marina Biotech Announces Key Additions to its Executive Management Team
February 14, 2017
Marina Biotech Completes Share Issuance at a Valuation of $0.29 Per Share
February 10, 2017
Marina Biotech Announces a License Agreement to SMARTICLES
February 7, 2017